Single-ascending Dose Study of Kylo-12 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

February 17, 2026

Study Completion Date

August 30, 2026

Conditions

Hypertriglyceridemia

Interventions

DRUG

Kylo-12

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

Chengdu Xinhua Hospital, Chengdu

All Listed Sponsors

lead

Kylonova (Xiamen) Biopharma co., LTD.

INDUSTRY

NCT06783881 - Single-ascending Dose Study of Kylo-12 in Healthy Subjects | Biotech Hunter | Biotech Hunter